NCT00959933View on ClinicalTrials.gov

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

May 31, 2001

Study Completion Date

May 31, 2001

Conditions
Chronic Hepatitis C
Interventions
DRUG

Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)

DRUG

Rebetol 200 Capsules (Schering Corporation, U.S.A.)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY